ライフサイエンスコーパス: phase II study

1 se III study), and circadian phase shifting (phase II study).

2 dvanced breast cancer in this signal-finding phase II study.

3 was not significantly superior to PC in this phase II study.

4 ge, 61 years; 33 males) were accrued for the phase II study.

5 ndent sets of serum samples in a prospective phase II study.

6 favorable changes in the lipid profile in a phase II study.

7 years) were prospectively enrolled onto this phase II study.

8 hich depletes antibodies, was effective in a phase II study.

9 e the rationale for conducting a multicenter phase II study.

10 OS) in a randomized, controlled, and blinded phase II study.

11 ic castration-resistant prostate cancer in a phase II study.

12 d toxicity and suggestions of benefit in one phase II study.

13 otecan in a multi-institutional, randomized, phase II study.

14 encouraging results in a single institution phase II study.

15 were enrolled in a multicenter, open-label, phase II study.

16 ustekinumab for psoriatic arthritis in this phase II study.

17 ally blinded, placebo-controlled, randomized phase II study.

18 xane, and capecitabine, in this multicenter, phase II study.

19 years, were treated in a limited institution phase II study.

20 Thirty-two patients were enrolled onto this phase II study.

21 This was a randomized, parallel-group, phase II study.

22 and therapeutic efficacy were evaluated in a phase II study.

23 ted therapy were enrolled in this single-arm phase II study.

24 lone in patients with advanced melanoma in a phase II study.

25 ment resolution in a randomized, multicenter phase II study.

26 ly reported efficacy and safety data for the Phase II study.

27 F (mDCF) regimen in a randomized multicenter phase II study.

28 agent reported to have modest activity in a phase II study.

29 eovascularization in a previous dose-finding phase II study.

30 ract cancer (BTC, n=37) were enrolled into a phase II -study.

31 gated, which have appeared superior in early phase II studies.

32 icity and definition of recommended dose for phase II studies.

33 ncing the present sirolimus formulation into phase II studies.

34 a continuous dosing schedule was optimal for phase II studies.

35 atment response will be further evaluated in phase II studies.

36 tient populations for anetumab ravtansine in phase II studies.

37 al ramifications for the predictive value of phase II studies.

38 nderstanding of the implications of positive phase II studies.

39 more effective design and interpretation of phase II studies.

40 for prophylactic use against group 2 IAVs in phase II studies.

41 ting that the antigens are eligible to enter Phase-II studies.

42 Of 351 phase II studies, 167 (47.6%) subsequent phase III trial

43 this prospective, double-blind, randomized, phase II study, 167 patients with refractory angina rece

44 andomized, double-blind, placebo-controlled, phase II study, 170 PsA patients with a psoriasis target

45 In this phase II study, 31 symptomatic patients age < 65 years w

46 In a phase II study, 39 healthy individuals from two US sites

47 n-label, multicenter (n = 13), parallel-arm, phase II study , 43 patients with HG BCG-refractory or r

48 Purpose Considering promising results in phase II studies, a randomized phase III trial was desig

49 In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was adminis

50 In a randomized Phase II study, adding olaratumab to doxorubicin chemoth

51 phase III studies are a number of innovative phase II studies, aimed at bringing immunotherapy forwar

52 In a previous phase II study an immunonutrient supplement was found to

53 hemoradiotherapy has been tested in numerous phase II studies and underpowered or flawed phase III st

54 every 21 days was selected for the expanded phase II study and is preferred for future phase III stu

55 e-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were intern

56 romal tumors (GISTs) treated in a randomized phase II study and to explore the potential relationship

57 We used data from a phase II study (AOST0221) of patients with osteosarcoma

58 In this randomized phase II study, application of a single defocused shock

59 Phase II studies are ongoing.

60 bjective response rates in three prospective phase II studies as first-line or second-line therapy fo

61 Two phase II studies assessed the efficacy of vismodegib, a

62 This phase II study assessed clofarabine monotherapy in older

63 This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib

64 This phase II study assessed the antitumor activity of hu14.1

65 PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everoli

66 This open-label, phase II study assessed the efficacy of vandetanib, a se

67 Our multicenter, single-arm, phase II study assessed the safety and clinical activity

68 laparib Expanded, an investigator-initiated, phase II study, assessed olaparib response in patients w

69 ned patients to targeted therapy in parallel phase II studies based on tumor molecular alterations.

70 tors should be cognizant of these factors in phase II studies before designing phase III trials.

71 must carefully be explored in well designed phase II studies before moving forward.

72 ixty-one patients treated in a nonrandomized phase II study (BRANCH) with concomitant or sequential (

73 A phase II study by the Southwest Oncology Group using con

74 n-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation

75 This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy

76 Phase II studies combining docetaxel with bevacizumab ha

77 A Phase II study comparing belatacept with cyclosporine (C

78 observations, we have initiated a randomized phase II study comparing the efficacy of standard cytoto

79 We conducted a systematic search of phase II studies conducted between 1999 and 2004 and com

80 ointing efficacy of 11betaHSD1 inhibitors in phase II studies could be explained by lack of selectivi

81 on stepwise multiple-regression analyses of phase II study data sets.

82 This randomized phase II study defines safety and response rate of epige

83 This phase II study demonstrates that BeGEV is an effective s

84 Results from phase II studies demonstrating a positive impact on seru

85 cine design and provides the rationale for a phase II study design using ESO(157-170) epitope or the

86 We report results of the phase II study designed to confirm this result.

87 hough several approaches have been tested in phase II study designs, few comparative data exist to gu

88 This prospective, multicenter phase II study did not specify the therapeutic regimen,

89 Adequate dose-finding phase II studies do not exist.

90 The recommended phase II study dose is 12.0 mg/m2 daily CIVI for 5 days.

91 ied in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 i

92 Patients and Methods This open-label phase II study enrolled adults with Ph(+) ALL who had re

93 This phase II study evaluated efficacy and safety of single-a

94 This open-label, single-arm, phase II study evaluated efficacy and tolerability of er

95 This randomized, placebo-controlled, phase II study evaluated entinostat combined with the ar

96 This randomized phase II study evaluated ixabepilone-based chemotherapy

97 This open-label randomized phase II study evaluated progression-free survival (PFS)

98 This phase II study evaluated the activity of combined treatm

99 This multicenter, open-label, phase II study evaluated the combination of bendamustine

100 This phase II study evaluated the efficacy and safety of sora

101 This preclinical and phase II study evaluated the efficacy and safety of the

102 This single-arm phase II study evaluated the efficacy of aflibercept (VE

103 This phase II study evaluated the efficacy of bendamustine in

104 This randomized phase II study evaluated the outcome of erlotinib with a

105 This phase II study evaluated the PD-L1 inhibitor avelumab in

106 This phase II study evaluated the safety and efficacy of sing

107 report results of a single-arm, multicenter, phase II study evaluating the safety and efficacy of sav

108 This phase II study examined safety and activity of panobinos

109 This phase II study examined the antitumor activity and safet

110 A single-agent phase II study examining a 200-mg dose given once every

111 -001 (EMERGE) trial is a global, multicenter phase II study examining the safety and efficacy of lena

112 In this phase II study, FFR-guided rate-response programming det

113 In this randomized phase II study, first-line treatment with T-DM1 for pati

114 In particular, guidance on the design of phase II studies for evaluating treatments in the critic

115 ntibody that has shown clinical benefit in a phase II study for the treatment of moderate-to-severe u

116 Phase II studies from multiple rather than single instit

117 This phase II study further evaluated the safety and efficacy

118 The phase II study GO27819 investigated the monovalent MET i

119 Our previous phase II study had shown the efficacy of induction chemo

120 Patients in our single arm phase II study had stage IV NSCLC with no more than six

121 Prospective phase II studies have been reported from several contine

122 Phase II studies have demonstrated efficacy and safety w

123 Phase II studies have indicated that high rates of respo

124 served median type I error for each disease, phase II studies have positive predictive values ranging

125 Phase II studies have tested drugs blocking EGFR, vascul

126 In this phase II study, healthy adults (aged 18-64 years) who pl

127 patients with recurrent glioblastoma in this phase II study; however, further investigation into biom

128 patient was enrolled onto an investigational phase II study; however, she developed progressive disea

129 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias.

130 These results provide the rationale for phase II studies in CLLs, lymphomas, and CD40-expressing

131 In two recently completed phase II studies in patients with relapsed Hodgkin lymph

132 Results from phase II studies in patients with stage IIIA non-small-c

133 and CRPC and may be a suitable end point for phase II studies in these settings.

134 cleoside analog, clofarabine, in two similar phase II studies in this group of patients.

135 cted an international multicenter randomized phase II study in 60 centers between December 2013 and N

136 European clinical trial authorization for a phase II study in a homogeneous patient cohort, with rep

137 This was a prospective phase II study in adults 18 to 59 years old with previou

138 uble-blind, placebo-controlled, dose-ranging phase II study in adults with symptomatic nHCM (New York

139 This is the largest phase II study in chordoma to date.

140 A phase II study in lung cancer assessed the activity of i

141 This was a randomized phase II study in patients with irinotecan-refractory co

142 We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gen

143 omab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade foll

144 1beta, has also shown promising results in a phase II study in recurrent/refractory pericarditis.

145 e results, a multi-institutional neoadjuvant phase II study in resectable pancreatic cancer is planne

146 and dexamethasone is being investigated in a phase II study in this setting and in newly diagnosed MM

147 ma Group (NLG) conducted a large prospective phase II study in untreated systemic PTCL.

148 We conducted a phase II study in which patients were administered treme

149 eliminary diagnostic efficacy data from this phase II study indicate that (68)Ga-OPS202 has high sens

150 In this phase II study, intracoronary nitrite infusion did not a

151 n this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dos

152 Our randomized phase II study investigated cisplatin with or without ce

153 This phase II study investigated TH-302 in combination with d

154 This phase II study investigated the activity of glembatumuma

155 This phase II study investigated the combination of TriMixDC-

156 This phase II study investigated the efficacy and safety of I

157 The recommended dose for phase II studies is 1,910 mg/m2 administered every 21 da

158 The recommended dose of CPX-351 for phase II study is 101 units/m(2).

159 A phase II study is in development.

160 omes were polysomnographic sleep efficiency (phase II study), latency to persistent sleep (phase III

161 The most common study design was a phase II study limited to previously untreated patients;

162 In this phase II study, low-dose decitabine showed promising res

163 out the del(5q) abnormality, enrolled in two phase II studies (MDS-003 and MDS-002) to determine whet

164 Data from a phase II study (n = 72) were used to model amyloid depos

165 In this phase II study (NCT00942747), temsirolimus was tested in

166 This phase II study (NCT01144455) evaluated gemcitabine plus

167 g favorable trial endpoints in a prospective Phase II study (NCT01402284).

168 tribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.

169 On the basis of these findings, phase II studies of EC145 have been initiated in patient

170 ected at a novel therapeutic target, overuse phase II studies of FDA-approved agents, and fail to inc

171 In phase II studies of targeted agents, multiple- versus si

172 Patients were participants in two phase II studies of the recombinant MAGE-A3 antigen comb

173 Phase II study of 72 patients with untreated de novo DLB

174 CONCLUSION This is the first phase II study of a new agent in sarcoma to include suff

175 We conducted a multicenter phase II study of a potent inhibitor of PKCbeta, enzasta

176 o chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipient

177 d the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neur

178 We therefore designed a phase II study of alisertib, a selective AAK inhibitor,

179 We conclude by calling for a prospective Phase II study of antidepressants in depressed glioma pa

180 A phase II study of ATG+G-CSF in patients with new-onset t

181 This phase II study of AUY922 and erlotinib did not meet its

182 A phase II study of bevacizumab (BVZ) plus irinotecan (CPT

183 Twenty-four children with brain tumors in a phase II study of bevacizumab and irinotecan underwent b

184 This is a phase II study of carboplatin area under the curve 5 wit

185 conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or wi

186 We performed a phase II study of cediranib in patients with recurrent g

187 A multicenter phase II study of cloretazine was conducted in patients

188 We conducted a phase II study of combination of the anti-insulin-like g

189 a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with

190 A recent phase II study of enzastaurin in patients with relapsed

191 We report the results of a randomized, phase II study of erlotinib alone or intercalated with c

192 rowth factor pathway with bevacizumab (B), a phase II study of GEMOX-B was undertaken to define effic

193 RTOG 0933 was a single-arm phase II study of HA-WBRT for brain metastases with pres

194 Here, in a phase II study of HSCT for poor-prognosis multiple scler

195 his prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.

196 PURPOSE An international phase II study of laromustine (VNP40101M), a sulfonylhyd

197 apsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab.

198 e compared in this randomized, double-blind, phase II study of men with CRPC.

199 l mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab (single dose)

200 We performed a phase II study of neoadjuvant chemotherapy with the obje

201 We performed a phase II study of oral vorinostat, a histone and protein

202 has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.

203 We report a multicenter phase II study of patients with metastatic melanoma (MM)

204 We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-

205 ducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in

206 S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFI

207 performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor

208 We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoi

209 studies (a phase I risankizumab study and a phase II study of risankizumab vs ustekinumab) were anal

210 We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and

211 r, we systematically evaluated images from a phase II study of sunitinib, a multitargeted TKI.

212 We conducted a multicenter phase II study of the fully human IGF-1R monoclonal anti

213 ed dose of ixabepilone for the initiation of phase II studies on the basis of these results is 50 mg/

214 and Methods In this multicenter, randomized, phase II study, patients with asymptomatic PCa were elig

215 In this double-blind, phase II study, patients with metastatic pancreatic canc

216 In this phase II study, patients with MF or SS with negligible t

217 In this multicenter, open-label, randomized, phase II study, patients with ovarian cancer that recurr

218 yses, randomized controlled trials, and some phase II studies published from 2005 through 2018.

219 In the majority of phase II studies published to date, postconditioning evo

220 Encouraging data from the phase II study resulted in the FDA granting accelerated

221 bladder-preservation studies, including five phase II studies (RTOG 8802, 9506, 9706, 9906, and 0233)

222 t eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to

223 Phase II studies suggested that omitting radiotherapy de

224 A previous phase II study suggested possible clinical benefit.

225 se I evaluations, and recent evidence from a phase II study suggests that co-administration of an ant

226 In the phase II study, tasimelteon reduced sleep latency and in

227 A phase II study testing ASK1240, that is, anti-CD40 antib

228 In this open-label phase II study, TH-302 300 mg/m(2) was administered intr

229 d data from a previously reported open-label phase II study that enrolled 34 men with advanced castra

230 trial was a randomized, placebo-controlled, phase II study that enrolled patients before chemotherap

231 ity and safety study, and in 21 canines in a phase II study that included a detailed objective assess

232 hological findings of the sentinel case in a phase II study that led to clinical development disconti

233 In this two-part phase II study, the efficacy and safety of vandetanib wa

234 We conducted a cooperative group phase II study to assess antitumor activity and toxicity

235 The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of ge

236 These data provide the basis for an ongoing phase II study to better define the activity of this reg

237 We performed an open-label phase II study to determine the safety and efficacy of P

238 We conducted a two-center phase II study to determine the safety of hemithoracic i

239 We did a phase II study to establish efficacy and physiological m

240 We conducted a phase II study to evaluate cetuximab for the treatment o

241 atients with advanced ACC were enrolled in a phase II study to evaluate the clinical activity of pemb

242 We undertook this phase II study to evaluate the efficacy and safety of MD

243 We performed a phase II study to evaluate the efficacy and safety of pe

244 We performed a phase II study to evaluate the efficacy of temozolomide

245 The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment

246 sly treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy

247 We conducted a randomized, noncomparative phase II study to measure the efficacy of cetuximab with

248 In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries,

249 ETHODS This open-label, multi-institutional, phase II study used a two-stage design.

250 e conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuva

251 The MTD recommended for phase II studies was 875 mg/m2/d for 5 days every 2 week

252 atelet aggregation than clopidogrel but in a phase II study was associated with increased risk for ve

253 ials and Methods This prospective single-arm phase II study was conducted between January 2015 and Ja

254 This phase II study was conducted by the SWOG cooperative gro

255 ernational, pivotal, single-arm, open-label, phase II study was conducted in patients with stage IB t

256 A multicenter phase II study was conducted to assess the efficacy of r

257 This phase II study was conducted to confirm safety and activ

258 A phase II study was conducted to determine the efficacy a

259 A phase II study was conducted to determine the efficacy a

260 This phase II study was conducted to determine the response r

261 PURPOSE A phase II study was conducted to determine the response r

262 The current multicenter phase II study was conducted to evaluate the activity an

263 A phase II study was conducted to evaluate the activity an

264 An open-label phase II study was conducted to evaluate the efficacy an

265 This phase II study was conducted to evaluate trebananib plus

266 This phase II study was conducted to further investigate the

267 A phase II study was conducted within the Pediatric Oncolo

268 This prospective phase II study was designed to assess disease control an

269 This multicenter phase II study was designed to estimate the response rat

270 eatment of TP53-defective CLL, a multicenter phase II study was developed to evaluate alemtuzumab and

271 double-blind, randomized, placebo-controlled phase II study was performed assessing clinical activity

272 A randomized, phase II study was performed in patients with AEGC to ex

273 A randomized, phase II study was performed in which patients in arm A

274 A phase II study was performed to determine the efficacy o

275 A 3:1 randomized phase II study was performed to evaluate carboplatin and

276 The dose selected for the phase II study was perifosine 50 mg/d plus bortezomib 1.

277 The purpose of this multicenter open label phase II study was to assess the efficacy and safety of

278 The primary objective of this phase II study was to characterize the safety and estima

279 The aim of this phase II study was to determine the efficacy of gemcitab

280 of this randomized, multicenter, open-label, phase II study was to determine tumor response to treatm

281 andomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab

282 The goal of this phase II study was to evaluate the efficacy of this comb

283 The goal of this randomized phase II study was to evaluate two different temozolomid

284 The aim of the present phase II study was to examine virologic response rates w

285 ENTS AND METHODS A prospective single-center phase II study was undertaken involving patients with un

286 In a single-arm phase II study we investigated the safety, efficacy, sur

287 In this phase II study, we combined cytarabine with R and B (R-B

288 In this phase II study, we investigated the efficacy and safety

289 Characteristics of the preceding phase II studies were reviewed to identify predictive fa

290 patients who received cetuximab as part of a phase II study were associated with high expression of t

291 ary end point for both phase III studies and phase II studies where a delay in progression is expecte

292 neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been d

293 h non-small-cell lung cancer in a randomized phase II study who received vandetanib, a VEGFR and epid

294 Phase II studies with biomarker evaluation are ongoing.

295 Initial phase II studies with TLR-9 vaccines conjugated to a rag

296 ust therefore be on performing well-designed phase II studies with uniform sets of basic entry and ev

297 This phase II study with ER+ breast cancer patients showed th

298 This was an open-label, two-stage, phase II study with two cohorts.

299 nd in combination with chemotherapy in three phase II studies, with promising results.

300 de >/= 2 oxaliplatin-induced neuropathy in a phase II study, with 22 patients receiving i.v. mangafod